Communicable Disease Case Reporting and Investigation Protocol

CARBAPENEMASE-PRODUCING ORGANISMS

I. IDENTIFICATION AND DEFINITION OF CASES

A. Clinical Description: Carbapenemase-producing organisms (CPOs) are an emerging and epidemiologically important public health threat. Infections with CPOs are difficult to treat and are associated with high mortality rates. Carbapenem antibiotics (doripenem, ertapenem, imipenem, and meropenem) are often used as the last line of treatment for infections caused by highly resistant gram-negative bacteria, including *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and many species from the order Enterobacterales. CPOs can contain mobile antibiotic-resistant elements that facilitate transmission of resistance to other gram-negative bacteria. Early detection and aggressive implementation of infection prevention and control strategies are necessary to prevent further spread of CPOs, especially novel CPOs.

B. Laboratory Criteria: Any bacterial isolate of *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, or any species from the order Enterobacterales (for example: *Klebsiella* spp., *Enterobacter* spp., *E. coli*, etc.) that tests positive or indeterminate for carbapenemase production by a phenotypic method, or positive for a carbapenemase resistance mechanism by molecular testing methods.

- Examples of phenotypic methods for the detection of carbapenemase production:
  - Carba NP positive
  - Metallo-β-lactamase testing (e.g., E-test) positive
  - Modified Carbapenem Inactivation Method (mCIM) positive or indeterminate
  - Carbapenem Inactivation Method (CIM) positive or indeterminate

- Examples of molecular methods for the detection of carbapenemase resistance mechanisms:
  - Commercial or validated laboratory-developed PCR for KPC, NDM, OXA, IMP, VIM or other carbapenemase
  - Xpert® Carba-R (KPC, NDM, OXA-48, VIM, or IMP)
  - Next Generation or other sequencing methods

C. Wisconsin Surveillance Case Definition:

- Confirmed: An isolate of *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, or any species from the order Enterobacterales that is positive for a carbapenemase resistance mechanism (KPC, NDM, VIM, IMP, OXA) by an FDA-approved or validated laboratory-developed test (e.g., PCR, Xpert® Carba-R), or sequencing method.

- Probable: An isolate of *Pseudomonas aeruginosa* or any species from the order Enterobacterales for which the phenotypic test is positive or indeterminate (examples of phenotypic tests include the metallo-β-lactamase test, Carba NP, Carbapenem Inactivation Method [CIM], or modified CIM), but the molecular testing is negative or not performed. (Note: phenotypic tests to detect carbapenemases are not recommended for use with isolates of *Acinetobacter baumannii*.)

D. Criteria to Distinguish a New Case:

A case should be counted as new if any of the following conditions are met:

- The patient tests positive for a different carbapenemase resistance mechanism (KPC, NDM, VIM, IMP, OXA) than previously identified.
- The isolate is from a clinical case where the previous isolate was from screening (for example, a patient with positive axilla/groin screening swab who later develops a wound infection).
- There is at least one year (365 days) between isolate collection dates.

II. REPORTING

A. Wisconsin Disease Surveillance Category II – Methods for Reporting: This disease shall be reported to the patient’s local health officer or to the local health officer’s designee within 72 hours of recognition of a case or suspected case, per Wis. Admin. Code § DHS 145.04(3)(b). Report electronically through the Wisconsin Electronic Disease Surveillance System (WEDSS), or mail or fax a completed Acute and Communicable Disease Case Report (F-44151) to the address on the form.
B. **Responsibility for Reporting:** According to Wis. Admin. Code § [DHS 145.04(1)], persons licensed under Wis. Stat. ch. 441 or 448, laboratories, health care facilities, teachers, principals, or nurses serving a school or day care center, and any person who knows or suspects that a person has a communicable disease identified in Appendix A.

C. **Clinical Criteria for Reporting:** None.

D. **Laboratory Criteria for Reporting:** Laboratory evidence of infection or colonization by culture or non-culture-based methods that meet the laboratory criteria. All positive results shall be reported and all positive isolates shall be forwarded to the Wisconsin State Laboratory of Hygiene (WSLH).

III. **CASE INVESTIGATION**
A. **Responsibility for case investigation:** It is the responsibility of the local or tribal health department (LTHD) to investigate or arrange for investigation of probable or confirmed cases as soon as is reasonably possible. A case investigation may include information collected by phone, in person, in writing, or through review of medical records or communicable disease report forms, as necessary and appropriate. The Wisconsin Healthcare-Associated Infections (HAI) Prevention Program within the Division of Public Health is available to assist or lead these investigations and support LTHDs and facilities through the case identification as well as ongoing response.

B. **Required Documentation:**
   - Complete the WEDSS disease incident investigation report, including appropriate disease-specific tabs. Upon completion of investigation, set WEDSS disease incident process status to “Sent to State.”
     - Isolates from the order Enterobacterales should be categorized under the WEDSS disease “Carbapenemase-Producing Carbapenem-Resistant Enterobacterales.”
     - Isolates from any other orders (including *Acinetobacter baumannii* and *Pseudomonas aeruginosa*) should be categorized under the WEDSS disease “Carbapenem-Producing Organisms.”

C. **Additional Investigation Responsibilities:** Some facilities that report a CPO will be eligible for fee-exempt colonization testing of patients or residents. This will be at the discretion of the Wisconsin Healthcare-Associated Infections (HAI) Prevention Program.

IV. **PUBLIC HEALTH INTERVENTIONS AND PREVENTION MEASURES**

B. Information on case and contact management can be found on the Wisconsin Department of Health Services Healthcare-Associated Infections Prevention Program Reportable MDROs website: www.dhs.wisconsin.gov/hai/reportable-mdro.htm.

C. Additional information on *Acinetobacter* in health care settings can be found at the CDC’s website: www.cdc.gov/hai/organisms/acinetobacter.html.

D. Additional information on *Pseudomonas aeruginosa* in health care settings can be found at the CDC’s website: www.cdc.gov/hai/organisms/pseudomonas.html.

E. Additional information on CRE in health care settings can be found at the CDC’s website: www.cdc.gov/hai/organisms/cre/cre-facilities.html.

V. **CONTACTS FOR CONSULTATION**
A. Local health departments and tribal health agencies: www.dhs.wisconsin.gov/lh-depts/index.htm

B. Bureau of Communicable Diseases, Wisconsin HAI Prevention Program: dhswihaipreventionprogram@wi.gov, 608-267-7711

C. Wisconsin State Laboratory of Hygiene: 1-800-862-1013; after hours emergency number: 608-263-3280
VI. RELATED REFERENCES


D. Wisconsin Department of Health Services, Division of Public Health. Antibiotic Resistance: www.dhs.wisconsin.gov/disease/aro.htm